Clinical trials: Advanced Tumor
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Squamous Non-small-cell Lung Cancer
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
This trial is a registrational Phase II/III randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1/VEGF bispecific antibody in first-line patients with locally…
- Trial name
- NCT07739199
- Testing
- BL-B01D1, PD-1/VEGF bispecific antibody, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Urothelial Bladder Cancer
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial…
- Trial name
- NCT04004221
- Testing
- Tislelizumab
- Where
- 27 sites in China, South Korea
- Volunteers
- 113 people
- Sponsor
- BeiGene
Gynecologic Cancer, Immunotherapy
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy
30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation.
- Conditions
- Gynecologic Cancer, Immunotherapy, Gut Microbiome
- Trial name
- NCT04957511
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Viome
Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
This is a first-in-man trial, in which BYL719 will be administered to adult patients with advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease has progressed despite standard therapy or for…
- Trial name
- NCT01219699
- Testing
- BYL719, Fulvestrant
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases
- Trial name
- NCT01009593
- Testing
- ABT-869, Sorafenib
- Where
- 163 sites in United States, Argentina and 27 more
- Volunteers
- 1,035 people
- Sponsor
- Abbott
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Pancreatic Cancer
AS703569 and Gemcitabine Combination in Advanced Malignancies
In clinical practice and research, combination of anticancer agents is often used to improve efficacy of treatment. In vitro and in vivo experiments have shown additive-synergistic anti-tumour effects of AS703569 treatment when…
- Trial name
- NCT01097512
- Testing
- AS703569/gemcitabine
- Where
- 3 sites in Belgium, France
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Lung Cancer
A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer
A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Participants with Advanced Lung Cancer
- Trial name
- NCT07673419
- Testing
- GK01 Injection
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Solid Tumors
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
This study will evaluate the safety, tolerability and preliminary anti-tumor activity of RO7296682 in combination with Atezolizumab in participants with advanced solid tumors.
- Trial name
- NCT04642365
- Testing
- RO7296682, Atezolizumab
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study of CM529D1 in Participants With Advanced Solid Tumors
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
- Trial name
- NCT07893171
- Testing
- CM529D1
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumors
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
To estimate the effect of food on the oral bioavailability and effect of diurnal variation on the pharmacokinetics of ABT-869.
- Trial name
- NCT00733187
- Testing
- ABT-869
- Volunteers
- 34 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055887
- Testing
- carboplatin, cisplatin, efaproxiral
- Where
- 22 sites in United States, Belgium and 2 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Locally Advanced or Metastatic Breast Cancer
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
- Trial name
- NCT05744687
- Testing
- SPH4336 Tablets 400mg
- Where
- 9 sites in China
- Volunteers
- 374 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Soft Tissue Sarcoma
Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide
This is an observational, non-randomized, open label, multicenter, phase IV study, which aims to reflect a real-life practice routinely used for the management of advanced soft tissue sarcoma after failure of anthracyclines…
- Trial name
- NCT01299506
- Where
- 5 sites in Netherlands
- Volunteers
- 102 people
- Sponsor
- PharmaMar
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
Gastric Cancer
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
This multicenter, randomized, adaptive Phase II/III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) compared to standard taxane (docetaxel or paclitaxel) treatment in participants with human epidermal…
- Trial name
- NCT01641939
- Testing
- Taxane, trastuzumab emtansine
- Where
- 148 sites in United States, Argentina and 26 more
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03735628
- Testing
- Copanlisib, Nivolumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Bayer
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.
- Trial name
- NCT01014936
- Testing
- MSC2156119J
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- EMD Serono
Advanced Solid Tumors, Breast Cancer
Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended…
- Trial name
- NCT06775236
- Testing
- SYS6010 jnjection, monotherapy chemotherapy, SYH2051 tablets
- Volunteers
- 410 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.